Publication & Citation Trends
Most Cited Works
Publications
73 total
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer PDF
Cited by 16
OpenAlex
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors PDF
Cited by 77
OpenAlex
EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer PDF
Cited by 67
OpenAlex
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment PDF
Cited by 491
OpenAlex
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Cited by 155
OpenAlex
Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma PDF
Cited by 32
OpenAlex
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations PDF
Cited by 28
OpenAlex
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules PDF
Cited by 125
OpenAlex
Research Topics
Advanced Breast Cancer Therapies
(35)
Estrogen and related hormone effects
(27)
Epigenetics and DNA Methylation
(18)
PI3K/AKT/mTOR signaling in cancer
(15)
Telomeres, Telomerase, and Senescence
(11)
Frequent Co-Authors
Affiliations
AstraZeneca (United Kingdom)
Tufts University
Tufts Medical Center
Roswell Park Comprehensive Cancer Center
Institute of Cancer Research